Current Neurology and Neuroscience Reports

, Volume 7, Issue 3, pp 223–230

Novel oral agents for multiple sclerosis

Article

DOI: 10.1007/s11910-007-0034-2

Cite this article as:
Burton, J.M. & O’Connor, P. Curr Neurol Neurosci Rep (2007) 7: 223. doi:10.1007/s11910-007-0034-2
  • 104 Views

Abstract

In 1993, interferon β-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trials have shown promise in efficacy and tolerability. This review assesses the results of the more thoroughly studied of these agents, some of which may soon be approved for use in multiple sclerosis.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Multiple Sclerosis Clinic, Division of NeurologySt. Michael’s HospitalTorontoCanada